natgillin/translations-raw huggingface dataset:
Severe renal impairment (GFR &lt; 30 ml/min/1.73 m2), anuria and patients undergoing dialysis.
Teško oštećenje bubrega (GFR &lt; 30 ml/min/1,73 m2), anurija i bolesnici na dijalizi.
Severe renal impairment with creatinine clearance &lt; 35 ml/min (see section 4.4).
Teško oštećenje bubrega s klirensom kreatinina &lt; 25 ml/min (vidjeti dio 4.4).
Severe renal impairment with creatinine clearance &lt; 35 ml/min (see section 4.4).
Teško oštećenje bubrega uz klirens kreatinina od &lt; 35 ml/min (vidjeti dio 4.4).
Severe renal impairment with creatinine clearance &lt; 35 ml/min (see section 4.4).
Teško oštećenje funkcije bubrega s klirensom kreatinina &lt; 35 ml/min (vidjeti dio 4.4).
Severe thrombocytopenias ( &lt; 50 x 109/l) are observed in about 20% to 30% of all patients.
Teška trombocitopenija ( &lt; 50 x 109/l) primijećena je u oko 20% do 30% svih bolesnika.
Sham (6.6%), p &lt; 0.001. Statistical superiority was achieved at week 3 and maintained up to and including week 26 (p &lt; 0.001) as shown in Table 6.
Statistička superiornost postignuta je u 3. tjednu i održala se do uključujući 26. tjedna (p &lt; 0,001) kao što je prikazano u Tablici 6.
Shortened infusions at doses &gt; 6 mg/kg have not been studied (see section 4.8).
Nisu provedena ispitivanja s kraćim trajanjem infuzije kod doza &gt; 6 mg/kg (vidjeti dio 4.8).
Shortening the treatment duration in patients with genotype 1 and high viral load (HVL) ( &gt; 800, 000 IU/ml) at baseline who become HCV RNA negative at week 4 and remain HCV RNA negative at week 24 should be considered with even more caution since the limited data available suggest that this may significantly negatively impact the sustained virologic response.
Skraćivanje trajanja liječenja za bolesnike s genotipom 1 i velikom količinom virusa (HVL engl. high viral load) ( &gt; 800 000 IU/ml) na početku liječenja, a koji su u 4. tjednu postali HCV RNK negativni i ostali HCV RNK negativni i u 24. tjednu, treba razmotriti s još većom pažnjom jer ograničeni podaci koji su dostupni, upućuju da skraćivanje trajanja liječenja može značajno negativno utjecati na trajni virološki odgovor.
Should patients experience an ANC &lt; 0.5 × 109/l for more than 4 weeks from the start of the last cycle, it is recommended that the dose for the next cycle be reduced by 25%.
Ako u bolesnika ABN iznosi &lt; 0,5 × 109/l dulje od 4 tjedna nakon početka posljednjeg ciklusa liječenja, u sljedećem se ciklusu preporučuje smanjiti dozu za 25%.
SIA Merck Sharp &amp; Dohme Latvija Tel: +371 67364 224 msd_lv@merck.com
SIA Merck Sharp &amp; Dohme Latvija Tel: +371 67364 224 msd_lv@merck.com.
SIA Merck Sharp &amp; Dohme Latvija Tel: +371 67364 224 msd_lv@merck.com
SIA „Merck Sharp &amp; Dohme Latvija“ Tel: +371 67364 224 msd_lv@merck.com
SIA Merck Sharp &amp; Dohme Latvija Tel: +371.67364.224
Sanofi Pasteur MSD, Tel: +46.8.564.888.60
Sialanar is not recommended in children aged &lt; 3 years in the symptomatic treatment of sialorrhoea (chronic pathological drooling) (see section 4.4).
Ne preporučuje se uporaba Sialanara u djece mlađe od 3 godine za simptomatsko liječenje sijaloreje (kroničnog patološkog slinjenja) (vidjeti dio 4.4).
Significance levels were defined as * p &lt; 0.05, **p &lt; 0.001, ***p &lt; 0.0001.
Razine značajnosti definirane su kao * p &lt; 0,05, **p &lt; 0,001, ***p &lt; 0,0001
Significant difference from placebo at the primary time point: * p &lt; 0.05, **p &lt; 0.001 ***p ≤ 0.0001 MCID HAQ-DI ≥0.22, MCID SF-36 PHS &gt; 5.42, MCID SF-36 MHS &gt; 6.33
Značajna razlika u odnosu na placebo u primarnoj vremenskoj točki: * p &lt; 0,05, **p &lt; 0,001, ***p ≤ 0,0001 MCID HAQ-DI ≥ 0,22, MCID SF-36 PHS &gt; 5,42, MCID SF-36 MHS &gt; 6,33
Significant haematological dysfunction, e.g. leucocytes &lt; 2.5 x 109/l, haemoglobin &lt; 9 g/dl, platelets &lt; 60 x 109/l, haemorrhagic diathesis or active bleeding disorder.
Značajna hematološka disfunkcija, npr. leukociti &lt; 2,5 x 109/l, hemoglobin &lt; 9 g/dl, trombociti &lt; 60 x 109/l, hemoragijska dijateza ili aktivni poremećaj krvarenja.
Significant hepatic dysfunction, e.g. &gt; 2 x upper limits of normal levels of aspartate aminotransferase, alanine aminotransferase or alkaline phosphatase; or bilirubin levels &gt; 1.25 x upper limits of normal.
Značajna disfunkcija jetre, npr. &gt; 2 x gornje granice normalnih vrijednosti aspartat aminotransferaze, alanin aminotransferaze ili alkalne fosfataze ili vrijednosti bilirubina &gt; 1,25 x gornje granice normale.
Significant improvement (p &lt; 0.001) versus vehicle was seen in postmenopausal women.
Značajno je poboljšanje (p &lt; 0,001) opaženo naspram podloge u žena u postmenopauzi.
Significant improvement (p &lt; 0.01) in the 6MWD was demonstrated at week 12 when the patients were asked to delay taking study medicinal product in order to reflect trough active substance concentration.
Značajno poboljšanje (p &lt; 0,01) 6MWD-a dokazano je u 12. tjednu, kada su bolesnici zamoljeni da odgode uzimanje ispitivanog lijeka kako bi test odražavao najniže koncentracije djelatne tvari.
Significant improvements from baseline were demonstrated in DLQI (p &lt; 0.001) and the physical and mental component scores of the SF 36 (p &lt; 0.001 for each component comparison).
Značajno poboljšanje u odnosu na početno stanje pokazalo se i u upitniku DLQI (p &lt; 0,001) i u rezultatima na fizičkoj i mentalnoj komponenti upitnika SF-36 (p &lt; 0,001 za svaku uspoređenu komponentu).
Significant increases in BMD at lumbar spine, total hip, femoral neck and hip trochanter were observed by 6 months (p &lt; 0.0001).
Značajna povećanja BMD lumbalne kralježnice, cijelog kuka, vrata bedrene kosti i trohantera kuka zabilježena su nakon 6 mjeseci (p &lt; 0,0001).
Significant renal dysfunction, e.g. nephrotic syndrome, serum creatinine &gt; 150 µmol/l, or creatinine clearance of &lt; 50 ml/min.
Značajna disfunkcija bubrega, npr. nefrotski sindrom, kreatinin u serumu &gt; 150 µmol/l ili klirens kreatinina &lt; 50 ml/min.
Significantly greater improvement in global QOL was observed in the crizotinib arm compared to the chemotherapy arm (overall difference in change from baseline scores 13.8; p-value &lt; 0.0001).
Značajno veće poboljšanje u globalnoj kvaliteti života zapaženo je u skupini krizotiniba u usporedbi s kemoterapijskom skupinom (ukupna razlika u promjeni u odnosu na početne bodove 13,8; p-vrijednost &lt; 0,0001).
Significantly more patients receiving 12.5 mg alogliptin and 1.000 mg metformin hydrochloride twice daily (59.5%) achieved target HbA1c levels of &lt; 7.0% compared to those receiving either 12.5 mg alogliptin twice daily alone (20.2%, p &lt; 0.001) or 1,000 mg metformin hydrochloride twice daily alone (34.3%, p &lt; 0.001) at Week 26.
U 26. tjednu je ciljne razine HbA1c od &lt; 7,0% postiglo značajno više bolesnika koji su primali 12,5 mg alogliptina i 1000 mg metforminklorida (59,5%) nego oni koji su primali ili samo alogliptin 12,5 mg dvaput na dan (20,2%, p &lt; 0,01) ili samo metforminklorid dvaput na dan (34,3%, p &lt; 0,001).
Significantly more patients receiving 25 mg alogliptin (44.4%) achieved target HbA1c levels of  7.0% compared to those receiving placebo (18.3%) at Week 26 (p &lt; 0.001).
U 26. tjednu je ciljne razine HbA1c od ≤7,0% postiglo značajno više bolesnika koji su primali alogliptin (44,4%) nego oni koji su primali placebo (18,3%) (p &lt; 0,001).
Significantly more patients receiving 25 mg alogliptin (44.4%) achieved target HbA1c levels of  7.0% compared to those receiving placebo (18.3%) at Week 26 (p &lt; 0.001).
U 26. tjednu je ciljne razine HbA1c od ≤7,0% postiglo značajno više bolesnika koji su primali alogliptin (44,4%) u usporedbi s onima koji su primali placebo (18,3%) (p &lt; 0,001).
Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of  7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004).
U 26. tjednu je ciljne razine HbA1c od ≤7,0% postiglo značajno više bolesnika koji su primali alogliptin (49,2%) nego oni koji su primali placebo (34,0%) (p &lt; 0,004).
Significantly more patients receiving 25 mg alogliptin plus 30 mg pioglitazone and metformin (33.2%) achieved target HbA1c levels of  7.0% compared to those receiving 45 mg pioglitazone and metformin (21.3%) at Week 52 (p &lt; 0.001).
U 52. tjednu je ciljne razine HbA1c od ≤7,0% postiglo značajno više bolesnika koji su uzimali 25 mg alogliptina s 30 mg pioglitazona i metforminom (33,2%) nego oni koji su uzimali 45 mg pioglitazona s metforminom (21,3%) (p &lt; 0,001).
Significantly more patients treated with Jakavi (20.9%) achieved a primary response (p &lt; 0.0001) compared to BAT (0.9%).
Značajno više bolesnika liječenih Jakavijem (20,9%) postiglo je primarni odgovor (p &lt; 0,0001) u usporedbi s NDT-om (0,9%).
Significantly more placebo recipients flared during Period B (33/62; 53%) than those maintained on abatacept (12/60; 20%; chi-square p &lt; 0.001).
Tijekom Razdoblja B bolest se razbuktala u značajno većem broju bolesnika koji su primali placebo (33/62; 53%) nego onih koji su održavani abataceptom (12/60, 20%; hi-kvadrat p &lt; 0,001).
Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 &gt; 150 μM).
Sildenafil je slabi inhibitor citokroma P450 izoformi 1A2, 2C9, 2C19, 2D6, 2E1 i 3A4 (IC50
Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 &gt; 150 μM).
Sildenafil je slabi inhibitor citokroma P450 izoformi 1A2, 2C9, 2C19, 2D6, 2E1 i 3A4 (IC50 &gt; 150 μM).
Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 &gt; 150 M).
Sildenafil je slab inhibitor izoformi 1A2, 2C9, 2C19, 2D6, 2E1 i 3A4 citokroma P450 (IC50 &gt; 150 m).
Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 &gt; 150 µM).
Sildenafil je slabi inhibitor citokroma P450 izoformi 1A2, 2C9, 2C19, 2D6, 2E1 i 3A4 (IC50
SIMBRINZA has not been studied in patients with severe renal impairment (CrCl &lt; 30 mL/min) or in patients with hyperchloraemic acidosis.
SIMBRINZA nije ispitana u bolesnika s teško oštećenom bubrežnom funkcijom (klirens kreatinina &lt; 30 ml/min) niti u bolesnika s hiperkloremijskom acidozom.
Simeprevir is extensively bound to plasma proteins ( 99.9%), primarily to albumin and, to a lesser extent, alfa-1-acid glycoprotein.
Simeprevir se opsežno veže na proteine plazme ( &gt; 99,9%), primarno na albumin te u manjoj mjeri na alfa-1-kiseli glikoprotein.
Similar proportions of patients in the once-daily and twice-daily abacavir arms of CAL30001 had GSS scores of &lt; 2 or 2 and successfully suppressed to &lt; 50 copies/mL by Week 48.
Slični udjeli bolesnika u skupinama koje su primale abakavir jednom ili dva puta dnevno u ispitivanju CAL30001 imali su GSS indekse &lt; 2 ili &gt; 2 te su uspješno do 48. tjedna postigli supresiju na &lt; 50 kopija/mL.
Similar results were observed at Week 12: 43.4%, 42.9%, and 31.7% respectively in 2 mg Resolor patients versus 26.9%, 27.2%, and 23.4% in placebo patients (p &lt; 0.001 vs placebo).
Slični rezultati primijećeni su u 12. tjednu: 43,4%, 42,9% odnosno 31,7% u bolesnika na lijeku Resolor 2 mg naspram 26,9%, 27,2% odnosno 23,4% u bolesnika na placebu (p &lt; 0,001 naspram placeba).
Similar results were observed at Week 12: 46.9% in 2 mg Resolor patients versus 19.0% in placebo patients (p &lt; 0.001 vs placebo).
Slični rezultati primijećeni su u 12. tjednu: 46,9% u bolesnika na lijeku Resolor 2 mg naspram 19,0% u bolesnika na placebu (p &lt; 0,001 naspram placebo).
Similar results were observed at Week 12: 46.9% in 2 mg Resolorpatients versus 19.0% in placebo patients (p &lt; 0.001 vs placebo).
Slični rezultati primijećeni su u 12. tjednu: 46,9% u bolesnika na lijeku Resolor 2 mg naspram 19,0% u bolesnika na placebu (p &lt; 0,001 naspram placeba).
Similar results were obtained on the incidence of cardiovascular hospitalisation with a risk reduction of 25.5% (p &lt; 0.0001).
Slični rezultati dobiveni su i za incidenciju hospitalizacije zbog kardiovaskularnih razloga, sa smanjenjem rizika od 25,5% (p &lt; 0,0001).
Simparica 5 mg chewable tablets for dogs 1.3–2.5 kg Simparica 10 mg chewable tablets for dogs &gt; 2.5–5 kg Simparica 20 mg chewable tablets for dogs &gt; 5–10 kg Simparica 40 mg chewable tablets for dogs &gt; 10–20 kg Simparica 80 mg chewable tablets for dogs &gt; 20–40 kg Simparica 120 mg chewable tablets for dogs &gt; 40–60 kg
Simparica 5 mg tablete za žvakanje za pse 1,3-2,5 kg Simparica 10 mg tablete za žvakanje za pse &gt; 2,5-5 kg Simparica 20 mg tablete za žvakanje za pse &gt; 5-10 kg Simparica 40 mg tablete za žvakanje za pse &gt; 10-20 kg Simparica 80 mg tablete za žvakanje za pse &gt; 20-40 kg Simparica 120 mg tablete za žvakanje za pse &gt; 40-60 kg
Simparica 5mg chewable tablets for dogs 1.3–2.5 kg Simparica 10 mg chewable tablets for dogs &gt; 2.5–5 kg Simparica 20 mg chewable tablets for dogs &gt; 5–10 kg Simparica 40 mg chewable tablets for dogs &gt; 10–20 kg Simparica 80 mg chewable tablets for dogs &gt; 20–40 kg Simparica 120 mg chewable tablets for dogs &gt; 40–60 kg
Simparica 5 mg tablete za žvakanje za pse 1,3-2,5 kg Simparica 10 mg tablete za žvakanje za pse &gt; 2,5-5 kg Simparica 20 mg tablete za žvakanje za pse &gt; 5-10 kg Simparica 40 mg tablete za žvakanje za pse &gt; 10-20 kg Simparica 80 mg tablete za žvakanje za pse &gt; 20-40 kg Simparica 120 mg tablete za žvakanje za pse &gt; 40-60 kg
Simulations using clinically relevant fasted conditions suggested that the mild CYP3A4 inhibitors azithromycin and fluvoxamine may increase the AUC of ibrutinib by &lt; 2-fold.
Simulacije u klinički značajnom stanju natašte ukazale su da slabi CYP3A4 inhibitori azitromicin i fluvoksamin mogu povećati AUC ibrutiniba za &lt; 2 puta.
Since it is highly unlikely that patients with inadequate viral responses will achieve a sustained virologic response (SVR), it is recommended that patients with HCV RNA &gt; 1,000 IU/ml at week 4 or week 12 discontinue therapy (refer to table 1).
S obzirom da kod bolesnika s neadekvatnim virološkim odgovorom postizanje trajnog virološkog odgovora (engl. sustained virologic response, SVR) nije vjerojatno, preporučuje se da bolesnici s HCV RNK &gt; 1000 IU/ml u 4. ili 12. tjednu prekinu terapiju (vidjeti Tablicu 1).
Since patients with an active hairy cell leukaemia mostly present with low blood counts, especially low neutrophil counts, more than 90% of the cases have transient severe neutropenias ( &lt; 1.0 x 109/l).
Budući da bolesnici s aktivnom leukemijom vlasastih stanica uglavnom imaju nisku krvnu sliku, osobito nizak broj neutrofila, u više od 90% slučajeva javlja se prolazna teška neutropenija ( &lt; 1,0 x 109/l).
Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans ( &lt; 2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions.
Budući da se pregabalin pretežno izlučuje mokraćom u nepromijenjenom obliku, da je u čovjeka podložan zanemarivom metabolizmu ( &lt; 2 % doze pronađe se u mokraći u obliku metabolita), da ne inhibira metabolizam lijekova in vitro i ne veže se za proteine u plazmi, nije vjerojatno da će izazivati ili ulaziti u farmakokinetičke interakcije.
Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans ( &lt; 2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions.
Budući da se pregabalin pretežno izlučuje mokraćom u nepromijenjenom obliku, da je u čovjeka podložan zanemarivom metabolizmu ( &lt; 2% doze pronađe se u mokraći u obliku metabolita), da ne inhibira metabolizam lijekova in vitro i ne veže se za proteine u plazmi, nije vjerojatno da će izazivati ili ulaziti u farmakokinetičke interakcije.
Since the number of subjects who were not Caucasian comprised only &lt; 3% of the total population (6 Black, 219 Caucasian), race was not evaluated as a covariate in the population pharmacokinetic analysis.
Budući da su ispitanici koji nisu bijele rase činili &lt; 3% ukupne populacije (6 crnaca, 219 bijelaca), rasa nije procjenjivana kao kovarijanta u populacijskoj farmakokinetičkoj analizi.
Site-directed mutagenesis of known NS5A RAVs showed that substitutions conferring a &gt; 100-fold reduction in velpatasvir susceptibility are M28G, A92K and Y93H/N/R/W in genotype 1a, A92K in genotype 1b, C92T and Y93H/N in genotype 2b, Y93H in genotype 3, and L31V and P32A/L/Q/R in genotype 6.
Ciljane mutageneze poznatih RAV-ova NS5A pokazale su da su supstitucije koje su dovele do smanjene osjetljivosti velpatasvitra za &gt; 100 puta bile M28G, A92K i Y93H/N/R/W u genotipu 1a, A92K u genotipu 1b, C92T i Y93H/N u genotipu 2b, Y93H u genotipu 3 te L31V iP32A/L/Q/R u genotipu 6.
Six patients (1 in the 12-week, 5 in the 24-week treatment group) with HCV RNA &lt; LLOQ at last measurement prior to transplant, were transplanted prior to SVR12 and were excluded from SVR12 and relapse analyses.
Nazivnik za relaps je broj pacijenata s HCV RNK &lt; LLOQ na njihovom posljednjem pregledu za vrijeme trajanja terapije.
sJIA Patients &lt; 30 kg
Bolesnici sa sJIA &lt; 30 kg
Skin &amp; subcutaneous tissue disorders
Poremećaji kože i potkožnog tkiva
Skin and subcutaneous tissue disorders Common ( &gt; 1/100, &lt; 1/10): sweating
Poremećaji kože i potkožnog tkiva Često ( &gt; 1/100 i &lt; 1/10): znojenje
Slovenská republika
C &amp; M Vetlink Plc.
Smoking induces CYP1A2 and has been shown to decrease the bioavailability of agomelatine, especially in heavy smokers ( &gt; 15 cigarettes/day) (see section 5.2).
Pušenje inducira CYP1A2 i dokazano je da smanjuje bioraspoloživost agomelatina osobito kod teških pušača (≥ 15 cigareta/dan) (vidjeti 5.2).
Smoking status &lt; 0.0001 6.5 times higher in never smokers than ever-smokers
Pušački status &lt; 0,0001 6,5 puta veći u osoba koje nikada nisu pušile u odnosu na osobe koje su ikada pušile
Some animals may also not show titres &gt; 0.5 IU/ml after single primary vaccination.
Isto tako, neke životinje nisu proizvele titar &gt; 0,5 IJ/ml nakon primarnog cijepljenja jednom dozom.
Some animals may also not show titres &gt; 0.5 IU/ml after single primary vaccination.
Isto tako, neke životinje nisu proizvele titar antitijela &gt; 0,5 IJ/ml nakon primarnog cijepljenja jednom dozom.
Some patients with moderately or severely impaired renal function (creatinine clearance &lt; 50 ml/min) may have increased eribulin exposure and may need a reduction of the dose.
Neki bolesnici s umjereno ili teško oštećenom funkcijom bubrega (klirens kreatinina &lt; 50 ml/min) mogu imati povećanu izloženost eribulinu te im može biti potrebno smanjiti dozu.
Sonidegib was highly bound to human plasma proteins (human serum albumin and alpha-1 acid glycoprotein) in vitro ( &gt; 97%), and binding was not concentration-dependent from 1 ng/ml to 2500 ng/ml.
Sonidegib je u velikoj mjeri vezan za proteine ljudske plazme (ljudski serumski albumin i alfa-1 kiseli glikoprotein) in vitro ( &gt; 97%), a vezanje nije bilo ovisno o koncentraciji od 1 ng/ml do 2500 ng/ml.
SonoVue is contraindicated in patients known to have right-to-left shunts, severe pulmonary hypertension (pulmonary artery pressure &gt; 90 mmHg), uncontrolled systemic hypertension, and in patients with adult respiratory distress syndrome.
SonoVue je kontraindiciran u bolesnika s poznatim desno-lijevim šantovima, teškom plućnom hipertenzijom (tlak plućne arterije &gt; 90 mmHg), nekontroliranom sistemskom hipertenzijom i kod bolesnika s respiratornim distres sindromom odraslih.
Special populations Elderly ( &gt; 65 years old)
Posebne populacije Stariji (≥65 godina)
Special populations: Patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) should be treated with caution.
Posebne populacije: bolesnike s teškim oštećenjem jetre (klirens kreatinina &lt; 30 ml/min) treba liječiti s oprezom.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: Not applicable.
Posebne mjere opreza koje mora poduzeti osoba koja primjenjuje veterinarsko-medicinski proizvod na životinjama: Nije primjenjivo.
Specific recommendations for management of treatment-emergent anaemia in adults are as follows: ribavirin should be reduced to 600 milligrams/day (200 milligrams in the morning and 400 milligrams in the evening) if either of the following apply: (1) a patient without significant cardiovascular disease experiences a fall in haemoglobin to &lt; 10 g/dl and ≥ 8.5 g/dl, or (2) a patient with stable cardiovascular disease experiences a fall in haemoglobin by ≥ 2 g/dl during any 4 weeks of treatment.
Posebne preporuke za hitnu obradu anemije u odraslih: Dozu ribavirina treba smanjiti na 600 mg/dan (200 mg ujutro i 400 mg uvečer) u bilo kojem od dva sljedeća slučaja: (1) ako u bolesnika bez izražene bolesti kardiovaskularnog sustava hemoglobin padne na &lt; 10 g/dl odnosno ≥8,5 g/dl ili (2) ako u bolesnika sa stabilnom bolesti kardiovaskularnog sustava hemoglobin padne za 2 g/dl u bilo koja 4 tjedna liječenja.
Spedra is contraindicated in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) (see sections 4.3 and 5.2).
Spedra je kontraindicirana u bolesnika s teškim oštećenjem bubrega (klirens kreatinina &lt; 30 ml/min) (vidjeti dijelove 4.3 i 5.2).
Splenic enlargement was reported to be related to filgrastim therapy in &lt; 3 % of patients.
Povećanje slezene povezano s primjenom filgrastima prijavljeno je u &lt; 3 % bolesnika.
Splenomegaly was reported to be related to filgrastim therapy in &lt; 3% of patients.
Splenomegalija je prijavljena kao povezana s terapijom filgrastimom u &lt; 3 % bolesnika.
Splenomegaly was reported to be related to filgrastim therapy in &lt; 3% of patients.
Splenomegalija povezana s liječenjem filgrastimom zabilježena je u &lt; 3% bolesnika.
Splenomegaly was reported to be related to filgrastim therapy in &lt; 3% of patients.
Splenomegalija povezana s primjenom filgrastima prijavljena je u &lt; 3% bolesnika.
SRH area &gt; 25 mm²
SRH površina &gt; 25 mm²
SRH area &gt; 25 mm²; MN titer ≥ 1:40;
Površina SRH &gt; 25 mm²; MN titar ≥ 1:40;
SRH area &gt; 25 mm²; MN titer ≥1:40;
Površina SRH &gt; 25 mm²; MN titar ≥ 1:40;
SRH area &gt; 25 mm²; MN titre ≥ 1:40;
Površina SRH &gt; 25 mm²; MN titar ≥ 1:40;
Standard criteria donor organs were defined as organs from a living donor, or a deceased donor with anticipated cold ischemia time of &lt; 24 hours and not meeting the definition of extended criteria donor organs.
Organi darivatelja koji zadovoljavaju standardne kriterije definirani su kao organi sa živih darivatelja ili preminulih donora s očekivanim trajanjem hladne ishemije &lt; 24 sata koji ne zadovoljavaju definiciju darivatelja organa prema proširenim kriterijima.
Staphylococcus aureus (CP8) strain SP 140 inactivated, expressing slime associated antigenic complex (SAAC) .............…………………………………………… &gt; 50 RED80**
Staphylococcus aureus (CP8) soj SP 140 inaktiviran, koji izražava kompleks antigena pridružen sluzi (SAAC)..................…………………………………………… &gt; 50 RED80
Staphylococcus aureus (CP8) strain SP 140 inactivated, expressing slime associated antigenic complex (SAAC)................................................................................................................ &gt; 50 RED80**
Staphylococcus aureus (CP8) soj SP 140 inaktiviran, koji izražava kompleks antigena pridružen sluzi (SAAC)............................................................................................................... &gt; 50 RED80
Staphylococcus spp.: Susceptible ≤ 0.125 mg/l; Resistant &gt; 0.125 mg/l,
Staphylococcus spp.: Osjetljiv ≤ 0,125 mg/l; Rezistentan &gt; 0,125 mg/l,
Starting dose of 600 mg, which can be titrated up to a maximum of 1,000/1,200 mg (1,000 mg for patients weighing &lt; 75 kg and 1,200 mg for patients weighing ≥ 75 kg) if well tolerated.
Početna doza od 600 mg koja se može titrirati do najviše 1000/1200 mg (1000 mg za bolesnike težine &lt; 75 kg i 1200 mg za bolesnike težine ≥ 75 kg) ako se dobro podnosi.